NCT03279120View on ClinicalTrials.gov

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Anti-Infective AgentsAnti-Retroviral AgentsContraceptive Usage
Interventions
DRUG

TFV/LNG IVR

Used for 90 days (Continuous or Interrupted)

DRUG

Placebo

Used for 90 days (Continuous or Interrupted)

Trial Locations (2)

23507-1627

Eastern Virginia Medical School, Norfolk

Unknown

Profamilia, Santo Domingo

Sponsors

Collaborators (1)

Agility Clinical, Inc.
All Listed Sponsors
collaborator

United States Agency for International Development (USAID)

FED

collaborator

Agility Clinical, Inc.

INDUSTRY

lead

CONRAD

OTHER